Current disease status-First occurrence of the myeloma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the myeloma Posts on Medivizor

Evaluating isatuximab for patients with recurrent or non-responding multiple myeloma

Posted by on Jan 8, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...

Read More

Evaluating lenalidomide-based regimens for elderly patients with multiple myeloma

Posted by on Oct 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with blood cancers

Posted by on Aug 23, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More

Comparison between two standard treatments for transplant-ineligible multiple myeloma

Posted by on Aug 2, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated whether a combination of bortezomib (Velcade), melphalan (Alkeran) and prednisone (Deltasone) was more effective than lenalidomide (Revlimid) and dexamethasone (Decadron) followed by lenalidomide maintenance for newly diagnosed multiple myeloma (MM). The main finding was that age and disease risk influenced the...

Read More

Does age influence the safety and effectiveness of stem cell treatment for patients with multiple myeloma?

Posted by on Jul 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...

Read More

Expert recommendations for the treatment of patients with multiple myeloma.

Posted by on Apr 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This article provided recommendations for the treatment of patients with multiple myeloma (MM). Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. High-dose chemotherapy followed by a stem cell transplant (SCT) remains a key part of treatment for patients with MM. There are two...

Read More

A combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma

Posted by on Apr 12, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...

Read More

Evaluating a treatment combination for patients with newly diagnosed and relapsed multiple myeloma

Posted by on Mar 28, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the combination D-VCd containing daratumumab (Darzalex), bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone (Decadron) in patients with multiple myeloma. This study concluded that this combination was safe and effective for these patients. Some background...

Read More

Searching for patients to try a new combination of treatments for multiple myeloma.

Posted by on Mar 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study will investigate the effectiveness of a new combination of chemotherapies: clarithromycin (Biaxin), lenalidomide (Revlimid) and dexamethasone (Decadron), for newly diagnosed multiple myeloma (MM). The main outcome that will be measured is survival without cancer worsening. This trial will take place in New York, the U.S....

Read More

Bortezomib plus lenalidomide for patients with multiple myeloma a after stem cell transplant

Posted by on Mar 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of bortezomib (Velcade) and lenalidomide (Revlimid) for patients with multiple myeloma after stem cell transplantation. This study found this combination is effective for these patients, with few side effects. Some background Multiple myeloma (MM) is a type of cancer...

Read More